Publications

BibTex format

@article{Maher:2023:10.1056/EVIDoa2300083,
author = {Maher, TM and Avram, C and Bortey, E and Hart, SP and Hirani, N and Molyneux, PL and Porter, JC and Smith, JA and Sciascia, T},
doi = {10.1056/EVIDoa2300083},
journal = {NEJM Evid},
title = {Nalbuphine Tablets for Cough in Patients with Idiopathic Pulmonary Fibrosis.},
url = {http://dx.doi.org/10.1056/EVIDoa2300083},
volume = {2},
year = {2023}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Nalbuphine for Cough with Idiopathic Pulmonary FibrosisIn patients with idiopathic pulmonary fibrosis, cough may have a negative impact on daily life. In a randomized, 22-day treatment period, placebo-controlled, crossover trial, extended-release nalbuphine (NAL ER), an opioid agonist-antagonist, was compared to placebo for cough control and adverse effects. During active treatment there was a 75.1% reduction in daytime objective cough frequency compared with 22.6% in the placebo treatment period. Nausea, fatigue, constipation, and dizziness were more common with NAL ER than with placebo.
AU  - Maher,TM
AU  - Avram,C
AU  - Bortey,E
AU  - Hart,SP
AU  - Hirani,N
AU  - Molyneux,PL
AU  - Porter,JC
AU  - Smith,JA
AU  - Sciascia,T
DO  - 10.1056/EVIDoa2300083
PY  - 2023///
TI  - Nalbuphine Tablets for Cough in Patients with Idiopathic Pulmonary Fibrosis.
T2  - NEJM Evid
UR  - http://dx.doi.org/10.1056/EVIDoa2300083
UR  - https://www.ncbi.nlm.nih.gov/pubmed/38320144
VL  - 2
ER  -

Download

Professor Toby Maher

Contact

Assistant

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)